Cn1 - Validating Survival Extrapolations in First Line Treatment of Renal Cell Carcinoma Using Literature-Based Conditional Survival Probabilities

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.018
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Causes of Death and Conditional Survival of Renal Cell Carcinoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?

Future Oncology
MedicineCancer ResearchOncology
2019English

Application of Dynamic Modeling for Survival Estimation in Advanced Renal Cell Carcinoma

PLoS ONE
Multidisciplinary
2018English

Survival Analysis of Pathological T3a Upstaging in Clinical T1 Renal Cell Carcinoma

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience

World Journal of Oncology
Cancer ResearchOncology
2019English

Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC)

PLoS ONE
Multidisciplinary
2015English

Recursive Calculation of Survival Probabilities

ASTIN Bulletin
AccountingEconomicsEconometricsFinance
1991English

Down-Regulation of TCF21 Is Associated With Poor Survival in Clear Cell Renal Cell Carcinoma

Neoplasma
Cancer Research
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy